EGFR T790M

This template is part of the ArticlePlaceholder extension. If you want to adjust it, please consider making your changes upstream.

Referenco

1. ↑ CIViC database
2. ↑ ^{2,00 2,01 2,02 2,03 2,04 2,05 2,06 2,07 2,08 2,09} CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/variants/34
3. ↑ OpenAlex, 26 jan. 2022, https://docs.openalex.org/download-snapshot/snapshot-data-format
4. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/646, Rociletinib in EGFR-mutated non-small-cell lung cancer
5. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/278, A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
6. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/963, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
7. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/965, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
8. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/966, Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
9. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/762, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
10. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1592, Osimertinib: First Global Approval
11. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1867, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
12. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1397, Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
13. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2157, EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
14. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2162, Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
15. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2163, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
16. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2164, Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
17. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2165, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
18. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/277, Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
19. ↑ ^{19,0 19,1} CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/967, In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
20. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2161, PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
21. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/6006, EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
22. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/238, EGFR T790M resistance mutation in non small-cell lung carcinoma
23. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/239, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
24. ↑ ^{24,0 24,1} CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1667, Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
25. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/240, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
26. ↑ ^{26,0 26,1} CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1391, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
27. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1863, Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
28. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2160, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
29. ↑ ^{29,0 29,1} CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2158, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
30. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/369, The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis
31. ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/370, Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients